Sorafenib

目录号:S7397 别名: BAY 43-9006

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib是Raf-1, B-Raf和VEGFR-2的多重激酶抑制剂,无细胞试验中IC50分别为6 nM, 22 nM和90 nM。

规格 价格 库存 购买数量  
RMB 1205.41 现货
RMB 2214.52 现货
RMB 5503.41 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献71篇:

客户使用该产品的12个实验数据:

  • (A) and (C) qPCR showing the levels of HMGA2 and SOX9 mRNA in Hep3B and Huh7 human HCC cells treated for 48 hours with 1 μM AZD6244, or 7.5 μM sorafenib relative to control-treated cells (Ctrl). (B) and (D) qPCR showing Hmga2 and Sox9 expression in p53−/−; HRAS(G12V) and p53−/−; Myc; Cas9; sgNf1 mouse liver cells. Drug treatment was the same as in (A). Error bars are s.d. of mean (n = 3). ***, P < .001.

    Gastroenterology, 2017, 152(5):1161-1173. Sorafenib purchased from Selleck.

    E-G, Shown are H&E, Ki67, and Tunel-stained representative sections from a vehicle or OTX015+panobinostat+sorafenib-treated GBM12 tumor

    Clin Cancer Res, 2018, 24(16):3941-3954. Sorafenib purchased from Selleck.

  • Western blotting of Mcl-1 in HCT116 cells treated with indicated agents for 24 hours. ABT-263, 5 μmol/L; ABT-737, 5 μmol/L; SAHA, 4 μmol/L; MS-275, 5 μmol/L; regorafenib, 40 μmol/L; sorafenib, 20 μmol/L; UCN-01, 1 μmol/L; sunitinib, 15 μmol/L.

    Cancer Res, 2018, 78(16):4704-4715. Sorafenib purchased from Selleck.

    Sorafenib in combination with metformin or the AMPK activator salicylate enhances AMPK activation. a, b, AMPK activation with the combination of sorafenib and metformin in LKB1 mutant KRAS mutant (A549 and H460) NSCLC cells (a), LKB1 wild-type KRAS mutant (H358) (b, left panel) or LKB1 mutant KRAS wild-type (H838) NSCLC cells (b, right panel). Cells were treated for 48 hr with sorafenib (1-3 uM), metformin (1–1.5 mM) or the combination of sorafenib and metformin with the same concentrations as were used for the individual treatments. c, AMPK activation with the combination of sorafenib and salicylate in LKB1 mutant KRAS mutant (A549 and H460) or LKB1 mutant KRAS wild-type (H838) NSCLC cells. Cells were treated for 48 hr with sorafenib (1–3 uM), salicylate (1–1.5 mM) or the combination of sorafenib and salicylate with the same concentrations as were used for the individual treatments. Cell lysates were harvested for western blot analysis and probed with the indicated antibodies.

    Int J Cancer 2012 10.1002/ijc.29113.. Sorafenib purchased from Selleck.

  • Inhibition of the MAPK signaling pathway results in downregulation of Plk-1 protein expression. (a) WB analysis for Plk-1 protein after treatment of human melanoma cell lines M14 and WM-115 with MEK 1/2 inhibitor PD98059 (10 μM), JNK inhibitor (16 μM), p38 inhibitor SB203580 (20 μM), and multikinase inhibitor sorafenib (10 μM) for 48 h showing significant reduction in the expression of Plk-1 protein after 48 hours. (b) Annexin V/PI staining of cells treated with MAPK inhibitors and induction of apoptosis. JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase kinase 1/2; Plk-1, polo-like kinase 1; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. Sorafenib purchased from Selleck.

    (A) were exposed to 200 uM gentamicin for various time periods. Immunoreactivity for phosphorylated JNK (green) and c-Jun (blue) in hair cells increased in a time-dependent manner. B. Hair cells from explants pre-treated with 500 nM sorafenib displayed a near complete inhibition of JNK activation at all time points analyzed.

    J Neurosci 2013 33(7), 3079-93. Sorafenib purchased from Selleck.

  • Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.

    Mol Cancer Res 2014 12(10), 1377-87. Sorafenib purchased from Selleck.

    HCC cell-derived exosomes reverse sorafenib-induced apoptosis in hepatoma carcinoma cells in vivo. a Tumors from mice treated with PBS (Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib + MHCC-97H-exosomes (Sora + 97H exo) were paraffin-embedded and sectioned, followed by staining of apoptotic cell by using TUNEL assays.

    J Exp Clin Cancer Res, 2016, 35(1):159. Sorafenib purchased from Selleck.

  • Sorafenib and PX-866 interact to suppress tumor growth in vivo. Mice were PO administered vehicle diluent, sorafenib (25 mg/kg), PX-866 (2 mg/kg), or the drug combination QD for 3 days. Animals were monitored daily and tumor volume determined every fifth day. Tumors from animals were isolated at day 15 and fixed, sectioned (10-um), and stained against proliferation (Ki67 staining), phospho-ERK1/2 and phospho-AKT staining, the levels of tumor cell apoptosis/cleaved caspase 3, as well as with H&E and 4′,6-diamidino-2-phenylindole (DAPI).

    Mol Pharmacol 2013 84(4), 562-71. Sorafenib purchased from Selleck.

    Effects of sorafenib or sunitinib on LicA-induced cell death, ER stress responses, PLCc1, Ca2+, and ROS in HepG2 cells. HepG2 cells were pretreated with sorafenib or sunitinib for 1 h, then treated with LicA or TG for 1 h (for P-eIF2a and P-PLCc1) or 24 h (for CHOP, ATF6a(p90), and caspase-4). The cell lysates were subjected to Western blot analyses using antibodies against CHOP, ATF6a(p90), caspase-4(C), P-eIF2a, and b-actin.

    Apoptosis 2014 19(4), 682-97. Sorafenib purchased from Selleck.

  • PLoS One 2013 8(1), e54595. Sorafenib purchased from Selleck.

    (C) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in HUH-7 and R-HUH-7 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (D) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in SK-HEP-1 and R-SK-HEP-1 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (E) HUH-7 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. (F) SK-HEP-1 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. Data were expressed as mean ± standard deviation of each experiment in triplicate. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. Sorafenib purchased from Selleck.

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述 Sorafenib是Raf-1, B-Raf和VEGFR-2的多重激酶抑制剂,无细胞试验中IC50分别为6 nM, 22 nM和90 nM。
靶点
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
体外研究

Sorafenib抑制野生型和V599E突变型B-Raf活性,IC50分别为22 nM 和 38 nM。Sorafenib也能有效抑制mVEGFR2 (Flk-1),mVEGFR3,mPDGFRβ,Flt3,和c-Kit,IC50分别为15 nM,20 nM,57 nM,58 nM,和68 nM。Sorafenib 能够较弱地抑制FGFR-1,IC50 为580 nM。Sorafenib对ERK-1,MEK-1,EGFR,HER-2,IGFR-1,c-Met,PKB,PKA,cdk1/cyclinB,PKCα,PKCγ,和pim-1没有活性。Sorafenib显著抑制NIH 3T3细胞中VEGFR2磷酸化,IC50 为 30 nM,也会抑制HEK-293细胞中Flt-3磷酸化,IC50 为20 nM。Sorafenib有效阻断大多数细胞中MEK 1/2 和 ERK 1/2磷酸化,但不阻断A549 或 H460细胞中该过程,同时不影响PKB通路的抑制。Sorafenib抑制HAoSMC 和 MDA-MB-231细胞的增殖,IC50分别为0.28 μM 和 2.6 μM。[1]除了抑制RAF/MEK/ERK信号通路,Sorafenib tosylate显著抑制eIF4E的磷酸化作用,并以MEK/ERK依赖的方式下调肝癌(HCC)细胞中Mcl-1水平。Sorafenib 抑制PLC/PRF/5 和HepG2细胞的增殖,IC50分别为6.3 μM 和 4.5 μM,并诱导显著的细胞凋亡。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NXvLV2M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi0TWM2OD1yLkCwNFAxOzB|IN88US=> MWjTRW5ITVJ?
MONO-MAC-6 NGriRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17MbWlEPTB;MD6wNFQyQCEQvF2= MVnTRW5ITVJ?
ALL-PO MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjIfVhWUUN3ME2wMlA{OTh2IN88US=> NWPSV4t4W0GQR1XS
NKM-1 M2PyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD3SmZKSzVyPUCuNFc1OTZizszN NXLWem02W0GQR1XS
CGTH-W-1 MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMkWwNlIh|ryP NH\pTodUSU6JRWK=
BB65-RCC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\RbGlEPTB;MD60O|A4OyEQvF2= NEfRVplUSU6JRWK=
NOS-1 M2DCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHTOpMzUUN3ME2wMlU3OzZizszN MWLTRW5ITVJ?
SH-4 NUW1R|AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwNkW2NVMh|ryP MVTTRW5ITVJ?
HOP-62 MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PPfGlEPTB;MD64OVA5QCEQvF2= NG\GWHNUSU6JRWK=
HCC2998 MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH1fFhtUUN3ME2wMlg5QDF6IN88US=> MYTTRW5ITVJ?
GDM-1 NUfU[VV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\0RWQxUUN3ME2wMlkxPjl6IN88US=> MUXTRW5ITVJ?
KM12 Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnHT5ZKSzVyPUGuNFIxQThizszN M{HjdXNCVkeHUh?=
LB2518-MEL MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFwMkC4NFkh|ryP M3Pw[3NCVkeHUh?=
NCI-H1436 Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M130SmlEPTB;MT6yNVY4QCEQvF2= MUjTRW5ITVJ?
EM-2 NW\lV4poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjFR4VKSzVyPUGuN|U2PzhizszN MXvTRW5ITVJ?
LAMA-84 MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTFwM{e2OFgh|ryP NUKwdXFnW0GQR1XS
KG-1 NGPtNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\zcWlEPTB;MT60O|k{PSEQvF2= M3W1SXNCVkeHUh?=
A388 M1\FSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDp[HRKSzVyPUGuOVkyPjVizszN NFXJ[2VUSU6JRWK=
no-10 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnnXWlJUUN3ME2xMlYyPzJ4IN88US=> M3L6fnNCVkeHUh?=
SF126 MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTOTWM2OD1zLk[zPFEzKM7:TR?= NWO1V5oyW0GQR1XS
MEG-01 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;5UpE6UUN3ME2xMlgxQThizszN NXfzS25OW0GQR1XS
A3-KAW MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwOEi0NkDPxE1? MVrTRW5ITVJ?
D-247MG NUm3dXpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnUUXRKSzVyPUKuNVQ1QCEQvF2= MXPTRW5ITVJ?
OVCAR-4 NGPiWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[5eWlEPTB;Mj6yNVM6OyEQvF2= M1PoeXNCVkeHUh?=
NCI-SNU-1 NWP6TItJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjlSoxKSzVyPUKuN|E3OiEQvF2= NH\UR3RUSU6JRWK=
NCI-H2171 M2n0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jifWlEPTB;Mj6zPVc3PCEQvF2= MYDTRW5ITVJ?
SIG-M5 NGnsZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\XTWM2OD1{LkSyNlQzKM7:TR?= MmjFV2FPT0WU
BE-13 M3\JVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJwNkm2NFkh|ryP NEXFUFFUSU6JRWK=
K052 NGHwTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr1SY1EUUN3ME2yMlc1PjF4IN88US=> MmPjV2FPT0WU
L-540 M4e0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzCTWM2OD1{Lke1O|g6KM7:TR?= NVm4dY9kW0GQR1XS
KMOE-2 MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\NTWM2OD1{LkixN|Uh|ryP MVjTRW5ITVJ?
MFH-ino NFzCcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPKendKSzVyPUKuPVIyQDVizszN NWO5[llyW0GQR1XS
HL-60 NULtTIVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fZZ2lEPTB;Mz6wOlI6QSEQvF2= MYjTRW5ITVJ?
HCC2218 Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTNwMUKwNFMh|ryP MVzTRW5ITVJ?
TE-5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInEXmlKSzVyPUOuNVMyPjJizszN NWf3O3h7W0GQR1XS
MZ1-PC NFjxU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFqy[2xKSzVyPUOuOFc2ODlizszN NF7ZW3BUSU6JRWK=
MRK-nu-1 NYPOOYIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fCSGlEPTB;Mz62NVQ3QCEQvF2= M2nIenNCVkeHUh?=
MZ7-mel M{LIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTNwNk[wPVkh|ryP NUC3TGJ3W0GQR1XS
BC-1 M3mzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTNwN{SwNkDPxE1? M4jTTXNCVkeHUh?=
ST486 M37ybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPXbVQ6UUN3ME2zMlg{Pjd|IN88US=> NFfzPXdUSU6JRWK=
KS-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPrNXBXUUN3ME2zMlg5OTl6IN88US=> MXXTRW5ITVJ?
SK-NEP-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTRwMU[4NVUh|ryP M134NHNCVkeHUh?=
BC-3 NUT2WlZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH3Onp7UUN3ME20MlI{OzlzIN88US=> NG\JW29USU6JRWK=
NCI-H1581 MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHneFJ3UUN3ME20MlI5Pzl6IN88US=> NHzEcZJUSU6JRWK=
MHH-PREB-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zOXWlEPTB;ND60NFQ5PCEQvF2= NUG5e3RvW0GQR1XS
NOMO-1 NWPhXZRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID1W2pKSzVyPUSuOFg6ODVizszN MX7TRW5ITVJ?
QIMR-WIL NH2wfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G5T2lEPTB;NT6wO|I6PCEQvF2= MnrIV2FPT0WU
SF539 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPwTWM2OD13LkGzNlI4KM7:TR?= NE[5N3JUSU6JRWK=
TE-12 NXe2c|hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf1eHFKSzVyPUWuNlQ6OjlizszN NWLC[olSW0GQR1XS
NCI-H510A MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjNTWM2OD13LkSxOlg2KM7:TR?= M4XLfHNCVkeHUh?=
JAR M3q1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTBTWM2OD13LkWwPFI1KM7:TR?= MlXSV2FPT0WU
no-11 NVTtV5lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi4TWM2OD13LkezOVY5KM7:TR?= NVSyUog5W0GQR1XS
BV-173 NYD0V|NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTVwOUW2PFIh|ryP NIXaZZZUSU6JRWK=
SR M{LjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrRTWM2OD14LkCwOlc5KM7:TR?= NEjyWVZUSU6JRWK=
MOLT-16 MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTZwMkWyOlYh|ryP MW\TRW5ITVJ?
MZ2-MEL M4XWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7nTWM2OD14LkOxPFM6KM7:TR?= MVjTRW5ITVJ?
SW954 NEjBc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTZwNEW4OlYh|ryP MX\TRW5ITVJ?
ML-2 MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;wc2VKSzVyPU[uOVI5PDlizszN Ml7nV2FPT0WU
OCI-AML2 NV3sdpF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjIU4pKSzVyPU[uOlExPjJizszN NVLEZldMW0GQR1XS
SIMA M2HXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzORWdKSzVyPUeuNFAyODFizszN Ml6zV2FPT0WU
DOHH-2 NGPISIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL4UI1KSzVyPUeuNFU3PzZizszN M1LiRnNCVkeHUh?=
697 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr0TWM2OD15LkC1PVg6KM7:TR?= NID5NYJUSU6JRWK=
NB1 M1H0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPjRnFKSzVyPUeuOFA1ODdizszN NGS3SFZUSU6JRWK=
D-392MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjRTWM2OD15Lk[yOlY{KM7:TR?= NWDZNHJRW0GQR1XS
ES8 NV;FS3pMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3oblZKSzVyPUeuO|Y2ODNizszN NVfC[4plW0GQR1XS
RPMI-8226 M2Lvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTdwOES1NVEh|ryP MVPTRW5ITVJ?
IST-MEL1 M4\YSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRThwNECwNFIh|ryP MUjTRW5ITVJ?
NB14 NHH3UlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTRe5poUUN3ME24MlY{OTN|IN88US=> NUHDVFVXW0GQR1XS
HD-MY-Z MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPJTWM2OD16Lk[zO|Q3KM7:TR?= MXrTRW5ITVJ?
TE-10 MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTabXBUUUN3ME24Mlc3OzV|IN88US=> NULHSmdNW0GQR1XS
LC-1F MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGybWFoUUN3ME25MlExQDN2IN88US=> NYD4eWZoW0GQR1XS
OS-RC-2 NUfaPGZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fwO2lEPTB;OT6xNVI1OyEQvF2= NG\tOXlUSU6JRWK=
NCI-SNU-16 NE\HWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfRRXJzUUN3ME25MlIyODJ4IN88US=> MYPTRW5ITVJ?
SHP-77 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlO0TWM2OD17LkexOlYzKM7:TR?= MUTTRW5ITVJ?
A4-Fuk NX\hfmtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHRcmFKSzVyPUmuO|U3OSEQvF2= NW[we45FW0GQR1XS
NB6 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M161O2lEPTB;OT63OlAzQSEQvF2= M{HsTXNCVkeHUh?=
JiyoyeP-2003 M2OzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXHZVJCUUN3ME2xNE41PzR3IN88US=> NGXlfWpUSU6JRWK=
DMS-114 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYWzU5JHUUN3ME2xNE42PDRzIN88US=> MX;TRW5ITVJ?
NB7 M{\pdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFyLke1NlYh|ryP MVTTRW5ITVJ?
NCI-H747 NFrmOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPoWoNKSzVyPUGxMlEzOTZizszN NF3XfVlUSU6JRWK=
HH NVXCSWxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHtTWM2OD1zMT6zPFc3KM7:TR?= MYTTRW5ITVJ?
EW-18 NVnFSlRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFzLkmwOFQh|ryP MVLTRW5ITVJ?
CHP-126 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFzLkm3N|gh|ryP NYX2N3E5W0GQR1XS
NTERA-S-cl-D1 NXKzcJU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDl[VFKSzVyPUGyMlAzPzhizszN NH7NRpZUSU6JRWK=
DEL MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLGUYYxUUN3ME2xNk4xQTh3IN88US=> M4Wyc3NCVkeHUh?=
LU-139 M4PO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDNWpFKSzVyPUGyMlU1OTNizszN M1zFbHNCVkeHUh?=
P30-OHK MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fxZmlEPTB;MUKuOVQ4QSEQvF2= M1O0dnNCVkeHUh?=
NCI-H1522 NILwT5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInJZ2lKSzVyPUGyMlc1PiEQvF2= NYqyNopnW0GQR1XS
NCI-H1299 NXTpWVR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLvellKSzVyPUGzMlI6OTFizszN MoXhV2FPT0WU
UACC-257 MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF|LkWxNlYh|ryP NX7zVoZRW0GQR1XS
Calu-6 M3PYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\1TWM2OD1zMz62NFQ3KM7:TR?= NFHl[VZUSU6JRWK=
NCI-H1882 NGPyS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnFZ3BUUUN3ME2xN{45PTV3IN88US=> NFXnXVFUSU6JRWK=
BB30-HNC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF2LkC2NFkh|ryP M{PXS3NCVkeHUh?=
ES1 MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjLO|Y1UUN3ME2xOE4yPTVzIN88US=> NELXTHdUSU6JRWK=
NCI-H1694 Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj3SY5KSzVyPUG0MlQ5OTFizszN NHPnUlFUSU6JRWK=
IST-SL1 MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED0dlFKSzVyPUG0Mlk3OTZizszN MYDTRW5ITVJ?
ECC4 NHjFPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDQTWM2OD1zNT6wOVU5KM7:TR?= NFjs[2lUSU6JRWK=
MDA-MB-134-VI M4nJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jMN2lEPTB;MUWuOFE{OSEQvF2= M2TMNHNCVkeHUh?=
SCH MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm3NnAzUUN3ME2xOU41PzJ6IN88US=> NEDMXohUSU6JRWK=
SK-N-FI NID3bpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXQc5hOUUN3ME2xOU43PTN2IN88US=> NEPxSJlUSU6JRWK=
HDLM-2 M1KyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF4LkC3NVQh|ryP NHnLd45USU6JRWK=
Ramos-2G6-4C10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLwTWM2OD1zNj6xNlk4KM7:TR?= NFWwNIxUSU6JRWK=
EW-24 M4rOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\2RmlEPTB;MU[uNVY3OSEQvF2= M3\Nc3NCVkeHUh?=
NCI-H2141 M4TRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HQdGlEPTB;MU[uNVg6KM7:TR?= NWnWTo9EW0GQR1XS
LC4-1 NHq4ZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPqTFB3UUN3ME2xOk43OTF7IN88US=> Mlq4V2FPT0WU
HT-144 NXfNc25VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF5LkCwOkDPxE1? M3v0bXNCVkeHUh?=
SK-MEL-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF5LkCwO|Ih|ryP MlP4V2FPT0WU
SCC-15 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7JWVFKSzVyPUG3MlE3OzhizszN NELEbItUSU6JRWK=
C8166 NWKzU2NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzqTWM2OD1zNz62PFM{KM7:TR?= MkfzV2FPT0WU
GOTO MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHrSGlKSzVyPUG3Mlg{PDRizszN Mle4V2FPT0WU
COR-L279 Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmmwTWM2OD1zOD6xN|YzKM7:TR?= NU\CU5oyW0GQR1XS
K-562 NUOzSFZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF6LkexOFMh|ryP NIj1V|lUSU6JRWK=
ES3 M4m0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTUTWM2OD1zOD64NFQyKM7:TR?= NYXpdmNUW0GQR1XS
LU-165 NG\yXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2H5fWlEPTB;MUmuO|AxQCEQvF2= NWrqRmZRW0GQR1XS
KM-H2 NYHiNopkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3vSoRXUUN3ME2yNE4{OTh2IN88US=> MUTTRW5ITVJ?
RL M4r0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJyLkm2PVIh|ryP M33Be3NCVkeHUh?=
EW-3 MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDqTWM2OD1{MT6xPFg6KM7:TR?= NU\aUIc4W0GQR1XS
A101D NE\PXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF23SFBKSzVyPUKxMlM4PTJizszN NWflSod4W0GQR1XS
HUTU-80 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJzLkO5OFYh|ryP MnTVV2FPT0WU
NCI-H23 NFzXXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\KbIxEUUN3ME2yNU4{QTl{IN88US=> M4rib3NCVkeHUh?=
PF-382 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\KXGlEPTB;MkGuOFQxOyEQvF2= M{HtRXNCVkeHUh?=
LB373-MEL-D NHywb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJzLkW2NVUh|ryP Mnv6V2FPT0WU
TE-8 NE[yZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJzLk[zPVQh|ryP NFLRe5lUSU6JRWK=
TE-9 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHvdpVKSzVyPUKxMlg2OTNizszN NYTNW|NYW0GQR1XS
Daudi MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\aPXBKSzVyPUKxMlk{ODRizszN M{DPfHNCVkeHUh?=
D-542MG NWr0T2lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEW0b3FKSzVyPUKyMlAzPTZizszN NUHle3hRW0GQR1XS
U-698-M NEDiTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrvTWM2OD1{Mj60OlA{KM7:TR?= NELJZ5dUSU6JRWK=
ES6 M4exRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJ{LkezOlYh|ryP MXLTRW5ITVJ?
DU-4475 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjvTWM2OD1{Mz64PFk4KM7:TR?= NXLMbm1MW0GQR1XS
ECC12 MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PDV2lEPTB;MkSuNlgxOyEQvF2= MnnyV2FPT0WU
C2BBe1 Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJ2LkOyN|kh|ryP MX\TRW5ITVJ?
IST-SL2 M2nmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\INGlEPTB;MkSuOFM3OiEQvF2= NIf6W4xUSU6JRWK=
DJM-1 M{PwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTITWM2OD1{ND61NlIyKM7:TR?= NIfYfZJUSU6JRWK=
DMS-153 MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJ2Lki2NVQh|ryP M{\LbHNCVkeHUh?=
NB13 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHsPWJKSzVyPUK1MlAzPjVizszN M3nnUXNCVkeHUh?=
SK-N-DZ MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJ4LkO0NVQh|ryP NWezZZFQW0GQR1XS
COR-L88 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPYTWM2OD1{Nj61O|k3KM7:TR?= M3v4NHNCVkeHUh?=
LU-65 Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ4Lki1N|Uh|ryP M4XOWHNCVkeHUh?=
TGBC1TKB MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n6XWlEPTB;Mk[uPVgzQCEQvF2= MkH4V2FPT0WU
THP-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X5bGlEPTB;MkeuNlE1OSEQvF2= M4nXRXNCVkeHUh?=
ONS-76 NIfROWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJ5LkOzNkDPxE1? M4nh[HNCVkeHUh?=
LC-2-ad NWftUWpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PtfmlEPTB;MkeuOlI{OSEQvF2= MYDTRW5ITVJ?
EW-13 MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHuUGpIUUN3ME2yPU4yPzR4IN88US=> M3LZUnNCVkeHUh?=
MS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWmxV2R{UUN3ME2zNE44Ojd6IN88US=> NV;jTHdzW0GQR1XS
NCI-H2227 NWHKVpB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C2TmlEPTB;M{CuPVgxPiEQvF2= M3f3PXNCVkeHUh?=
LXF-289 NF;2UlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjrTWM2OD1|MT60OFkzKM7:TR?= MonvV2FPT0WU
MC116 MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rhUWlEPTB;M{KuNFgzPiEQvF2= NGTISXRUSU6JRWK=
EVSA-T MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTZ[4xKSzVyPUOyMlI2QDVizszN M{izc3NCVkeHUh?=
CTB-1 M{L4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XTSmlEPTB;M{OuNVExOSEQvF2= M3TRNnNCVkeHUh?=
COLO-320-HSR NHzIc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;GTWM2OD1|Mz6xOlA{KM7:TR?= MmDiV2FPT0WU
NCI-H2196 NYezWGNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrkcpZLUUN3ME2zN{4zPTV5IN88US=> NYfhVmV[W0GQR1XS
LB2241-RCC NWP6c4RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3HTWM2OD1|Mz6zNVM2KM7:TR?= MnvVV2FPT0WU
LS-513 MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTN|Lki2N|gh|ryP MV7TRW5ITVJ?
LP-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoC2TWM2OD1|Mz65PVU3KM7:TR?= M3zKN3NCVkeHUh?=
A253 M{K4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTN2LkKyPVYh|ryP MmXvV2FPT0WU
SK-MM-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPYTWM2OD1|ND65OFUyKM7:TR?= M3fiSXNCVkeHUh?=
NCI-H1963 NXPwVINYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fiN2lEPTB;M{WuN|A4OiEQvF2= NVKwSlRKW0GQR1XS
MMAC-SF M2DzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\FTWM2OD1|NT64O|g2KM7:TR?= NXTzcVJ[W0GQR1XS
LB831-BLC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\ETWM2OD1|Nj6wOlU1KM7:TR?= Ml\jV2FPT0WU
WSU-NHL NGq0W2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:yeodMUUN3ME2zOk4yPjRizszN NHTSTmhUSU6JRWK=
CESS NIPzVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;z[GlEPTB;M{[uNlg1QCEQvF2= M3HIdXNCVkeHUh?=
NEC8 MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTN4LkW4N|Uh|ryP MX7TRW5ITVJ?
KNS-42 NXHITJcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjXPZdKSzVyPUO3MlEzOzdizszN NV73T5NtW0GQR1XS
MHH-CALL-2 NVHPZVY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHOTWM2OD1|Nz6xPFIyKM7:TR?= MkW5V2FPT0WU
K5 M2Pv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm4S29QUUN3ME2zPE41OyEQvF2= M3zBWHNCVkeHUh?=
CP66-MEL M{LFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDNNINKSzVyPUO5MlA4OzNizszN MVzTRW5ITVJ?
OPM-2 M2XGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTN7Lki0N|Ih|ryP NYKzWohIW0GQR1XS
IST-MES1 NVrEN|JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrXSYdMUUN3ME20NE4{ODl4IN88US=> NUix[29RW0GQR1XS
EC-GI-10 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfPdJdYUUN3ME20NU42QDB3IN88US=> NYjIXmt7W0GQR1XS
CTV-1 NWDhWYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm1fppKSzVyPUSyMlg1ODZizszN Mn\LV2FPT0WU
DG-75 NWqxRnduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DMXmlEPTB;NEOuO|U6PSEQvF2= M13HU3NCVkeHUh?=
KNS-81-FD MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;ocYpKSzVyPUS1MlQxPThizszN NU\MU5I{W0GQR1XS
NCI-H82 M4fPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjTfVFKSzVyPUS1MlU4PThizszN NV3GRo5UW0GQR1XS
RPMI-8866 NXPlUo94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PseWlEPTB;NE[uNVg4OyEQvF2= M1r0OnNCVkeHUh?=
ACN MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTR4LkSzOEDPxE1? MWHTRW5ITVJ?
NCI-H1395 MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHh[npKSzVyPUS2MlQ4PTZizszN NFX2cWpUSU6JRWK=
NCI-H209 M{n5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fnb2lEPTB;NEeuNVQxPSEQvF2= NITpN4NUSU6JRWK=
TGW MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH76Sm1KSzVyPUS5MlA4QTFizszN Mny4V2FPT0WU
NCI-H748 NYW2UGJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmH1TWM2OD12OT60O|U{KM7:TR?= MlnUV2FPT0WU
EKVX MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3iOlVKSzVyPUS5MlY3OjhizszN NE[2cm5USU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究 Sorafenib(~60 mg/kg)口服给药,对各种人肿瘤异种移植模型,包括MDA-MB-231,Colo-205,HT-29,DLD-1,NCI-H460,和A549表现出广谱的、剂量依赖性抗肿瘤活性,而没有毒性。与抗肿瘤功效相联系,Sorafenib 治疗有效抑制HT-29 和 MDA-MB-231异种移植物中MEK 1/2磷酸化和pERK 1/2水平,但对Colo-205异种移植物没有作用,并且也能显著抑制MDA MB-231,HT-29 和 Colo-205肿瘤异种移植物中肿瘤微血管面积(MVA)和微血管密度(MVD)。[1] 在SCID小鼠体内,Sorafenib治疗对PLC/PRF/5肿瘤异种移植产生剂量依赖性生长抑制,10 mg/kg和30 mg/kg剂量下,TGIs分别为49%和78%,与ERK 和 eIF4E磷酸化抑制,微血管面积减少,和肿瘤细胞凋亡的诱导相一致。[2] Sorafenib通过下调NF-κB介导的Mcl-1 和 cIAP2表达的作用机制使bax-/-细胞对TRAIL剂量依赖性敏感。 Sorafenib (30-60 mg/kg) 与 TRAIL (5 mg/kg)结合对TRAIL抗性HCT116 bax-/-和HT29肿瘤异种移植物表现出显著的功效。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

生化检测:

重组杆状病毒表达的Raf-1 (残基305–648)和 B-Raf (残基 409–765)以融合蛋白纯化。全长人MEK-1由PCR产生,并以大肠杆菌裂解物中的融合蛋白纯化。将Sorafenib加入到含Raf-1 (80纳克),或B-Raf (80 纳克) 以及MEK-1 (1 微克) 混合物的实验缓冲液[20 mM Tris (pH 8.2),100 mM NaCl,5 mM MgCl2,和0.15% β-巯基乙醇]中,DMSO终浓度为1%。加入25微升10 μM γ[33P]ATP (400 Ci/mol)启动Raf激酶试验(终体积50微升),并在32 °C下培育25分钟。磷酸化的MEK-1通过过滤到磷酸纤维素板上采集,使用1%磷酸洗掉未结合的放射性。微波炉加热干燥后,使用β型板计数器量化过滤器结合放射性。人VEGFR2 (KDR)激酶域被表达,并从Sf9裂解物中纯化。VEGFR2的时间分辨荧光分析法能量转移测试在96孔不透明板中以时间分辨荧光分析法能量转移格式进行。最终反应条件如下:1 到10 μM ATP,25 nM poly GT生物素,2 nM 铕标记的磷酸(p)-酪氨酸抗体(PY20),10 nM APC,1% DMSO 终浓度的1 到 7 nM 细胞质激酶域,50 mM HEPES (pH 7.5),10 mM MgCl2,0.1 mM EDTA,0.015% Brij-35,0.1 毫克/毫升BSA,和0.1% β-巯基乙醇。反应体积为100微升,加入酶启动反应。反应启动~1.5 到 2.0小时后,板以615 和 665 nM在Perkin-Elmer VictorV多标记分析仪上读数。信号按如下比率计算:对每孔(665 nm/615 nM) × 10,000。对IC50的产生,在酶起始反应之前加入Sorafenib。50倍的库存板由Sorafenib在50% DMSO/50%蒸馏水溶液中连续稀释制得。最终Sorafenib在1% DMSO中的浓度范围为10 μM 到 4.56 nM。
细胞实验:[1]
+ 展开
  • Cell lines: MDA-MB-231,和 HAoSMC
  • Concentrations: 溶解于DMSO,终浓度为~10 μM
  • Incubation Time: 72小时
  • Method: 细胞在逐渐增加浓度的Sorafenib下暴露72小时。细胞数通过Cell TiterGlo ATP发光测定试剂盒进行定量。该试验通过测定基于细胞中ATP量的发光信号,测量每孔中的活细胞。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 雌性 NCr-nu/nu 小鼠,皮下植入MDA-MB-231,Colo-205,HT-29,H460,或 A549 细胞
  • Formulation: 以4倍(4 ×储备溶液,稀释为1 ×)溶解于聚氧乙烯蓖麻油/乙醇(50:50)
  • Dosages: ~60 mg/kg
  • Administration: 口服,每天一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 63 mg/mL warmed (135.53 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+45% PEG 400+ddH2O
3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 464.82
化学式

C21H16ClF3N4O3

CAS号 284461-73-0
稳定性 powder
in solvent
别名 BAY 43-9006

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03730675 Not yet recruiting Hepatocellular Carcinoma|Portal Vein Tumor Thrombosis Zhongda Hospital November 2018 Not Applicable
NCT03645980 Recruiting Hepatocellular Carcinoma Johannes Gutenberg University Mainz|Leap Therapeutics Inc. October 10 2018 Phase 1|Phase 2
NCT03644511 Not yet recruiting Hepatocellular Carcinoma Bayer October 30 2018 --
NCT03606590 Recruiting Hepatocellular Carcinoma NovoCure Ltd. September 2018 Phase 2
NCT03630120 Recruiting Thyroid Cancer|Thyroid Cancer Medullary|Differentiated Thyroid Cancer|Papillary Thyroid Cancer|Follicular Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma H. Lee Moffitt Cancer Center and Research Institute August 6 2018 Phase 2
NCT03582618 Recruiting Hepatocellular Carcinoma|Advanced Cancer TaiRx Inc. July 12 2018 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Raf Signaling Pathway Map

相关Raf产品

Tags: 购买Sorafenib | Sorafenib供应商 | 采购Sorafenib | Sorafenib价格 | Sorafenib生产 | 订购Sorafenib | Sorafenib代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID